Inclusion Criteria:  Age: 18 to 70 years old, no gender limitation; Histopathological diagnosis of locally advanced, recurrent or metastatic HAS (pathological histomorphology and immunohistochemical diagnosis of AFP, sal-like 4(SALL4), Hep, glypican-3(GPC3), etc.); Immunohistochemical(IHC) human epidermal growth factor receptor-2 (HER2) negative persons; HER2 positive is defined as IHC 3+ or IHC 2+ and fluorescence in situ hybridization(FISH)+, and FISH positive is defined as the ratio of HER2 gene copy number to chromosome 17 centromere(CEP17) signal number ≥2.0; According to the RECIST 1.1 standard, at least one measurable lesion (spiral CT scan ≥10mm); ECOG performance status(PS): 0-2 points; The expected survival time is ≥3 months;  The main organs are functionally normal, without serious blood, heart, lung, liver, kidney dysfunction and immune deficiency disease. The blood test meets the following requirements; (1) Routine blood examination, which must be met (no blood transfusion within 14 days);  HGB≥100g/L; WBC≥4.0×10^9/L; absolute neutrophil count(ANC) ≥2.0×10^9/L; PLT≥2.0×10^9/L; (2) The biochemical inspection must meet the following standards: BIL≤1.5 times the upper limit of normal (ULN); Alanine aminotransferase(ALT) and aspartate aminotransferase(AST)≤2.5×ULN; if there is liver metastasis, ALT and AST≤5×ULN; serum Cr≤1.5×ULN, endogenous creatinine clearance≥50ml/min (Cockcroft-Gault formula); (3) Occult blood in stool (-); (4) Urine routine is normal, or urine protein <(++), or 24-hour urine protein <1.0g;  The coagulation function is normal, without active bleeding and thrombosis disease;  International standardized ratio INR≤1.5×ULN; Partial thromboplastin time APTT≤1.5×ULN; Prothrombin time PT≤1.5×ULN; Female subjects with fertility and male subjects whose partner is a female of childbearing age who need to take effective contraceptive measures during the study treatment period and at least 6 months after the last use of the study drug; Subjects voluntarily participate in this study and sign an informed consent form (ICF); Those who have good compliance and can follow up as required by the plan.  Exclusion Criteria:  Various types of liver inflammatory diseases (especially hepatitis A, B, and C viral hepatitis active period) and other diseases that may produce AFP such as liver cirrhosis; Germ cell tumors; Have previously received any regimen of palliative chemotherapy for gastric cancer; Have previously received apatinib treatment; S-1 and/or oxaliplatin have been used in the past 6 months; Those who have hypertension and cannot be reduced to the normal range after treatment with antihypertensive drugs (shrinking Pressure>140mmHg or diastolic pressure>90mmHg); Suffering from coronary heart disease ≥2 grade, arrhythmia corrected QT interval(QTc) interval prolonged male> 450ms, female;>470ms) and cardiac insufficiency; There are many factors that affect the absorption of oral drugs (such as inability to swallow, nausea and vomiting, chronic abdominal Diarrhea and intestinal obstruction, etc.); Patients at risk of gastrointestinal bleeding or those with a history of gastrointestinal bleeding within 1 month; Abnormal blood coagulation function (INR>1.5×ULN, activated partial thromboplastin time(APTT)>1.5×ULN), those with bleeding tendency; Those with thrombotic diseases or receiving anticoagulant treatment; Those with peripheral sensitive neuropathy with dysfunction; Central nervous system metastasis; Pregnant or lactating women; Those who have participated in other clinical research in the past 30 days; Other patients considered by the treating physician to be unsuitable for inclusion